Mucopolysaccharidosis type IVA (MPS
IVA) is a rare disease caused
by mutations in the gene encoding the lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase (GALNS). We report here
two GALNS pharmacological chaperones, ezetimibe and pranlukast, identified
by molecular docking-based virtual screening. These compounds bound
to the active cavity of GALNS and increased its thermal stability
as well as the production of recombinant GALNS in bacteria, yeast,
and HEK293 cells. MPS IVA fibroblasts treated with these chaperones
exhibited increases in GALNS protein and enzyme activity and reduced
the size of enlarged lysosomes. Abnormalities in autophagy markers
p62 and LC3B-II were alleviated by ezetimibe and pranlukast. Combined
treatment of recombinant GALNS with ezetimibe or pranlukast produced
an additive effect. Altogether, the results demonstrate that ezetimibe
and pranlukast can increase the yield of recombinant GALNS and be
used as a monotherapy or combination therapy to improve the therapeutic
efficacy of MPS IVA enzyme replacement therapy.
Coronavirus Disease 2019 (Covid-19) was first described in December 2019 in Wuhan, Hubei Province, China; and produced by a novel coronavirus designed as the acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Covid-19 has become a pandemic reaching over 1.3 million confirmed cases and 73,000 deaths. Several efforts have been done to identify pharmacological agents that can be used to treat patients and protect healthcare professionals. The sequencing of the virus genome not only has offered the possibility to develop a vaccine, but also to identified and characterize the virus proteins. Among these proteins, main protease (Mpro) has been identified as a potential therapeutic target, since it is essential for the processing other viral proteins. Crystal structures of SARS-CoV-2 Mpro and inhibitors has been described during the last months. To describe additional compounds that can inhibit SARS-CoV-2 Mpro, in this study we performed a molecular docking-based virtual screening against a library of experimental and approved drugs. Top 10 hits included Pictilisib, Nimorazole, Ergoloid mesylates, Lumacaftor, Cefuroxime, Cepharanhine, and Nilotinib. These compounds were predicted to have higher binding affinity for SARS-CoV-2 Mpro than previously reported inhibitors for this protein, suggesting a higher potential to inhibit virus replication. Since the identified drugs have both pre-clinical and clinical information, we consider that these results may contribute to the identification of treatment alternative for Covid-19. Nevertheless, in vitro and in vivo confirmation should be performed before these compounds could be translated to the clinic.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.